Vallon Pharmaceuticals, Inc. (VLON): Price and Financial Metrics
GET POWR RATINGS... FREE!
VLON Stock Price Chart Interactive Chart >
VLON Price/Volume Stats
|Current price||$0.56||52-week high||$3.45|
|Prev. close||$0.56||52-week low||$0.34|
|Day high||$0.60||Avg. volume||2,470,812|
|50-day MA||$1.35||Dividend yield||N/A|
|200-day MA||$1.84||Market Cap||3.83M|
Vallon Pharmaceuticals, Inc. (VLON) Company Bio
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. The company was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
Most Popular Stories View All
VLON Latest News Stream
|Loading, please wait...|
VLON Latest Social Stream
View Full VLON Social Stream
Latest VLON News From Around the Web
Below are the latest news stories about Vallon Pharmaceuticals Inc that investors may wish to consider to help them evaluate VLON as an investment opportunity.
- T opline data for p ivotal abuse study of the C ompany’s lead investigational program ADAIR expected this quarter
Vallon Pharmaceuticals press release (VLON): FY 2021 Net loss was $9.3M.Cash, cash equivalents and marketable securities of ~$7.5M
Even with Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) stock down 13% this week, insiders who bought recently netted around US$20k
Vallon Pharmaceuticals, Inc. ( NASDAQ:VLON ) insiders who acquired shares over the previous 12 months, can probably...
– Live video webcast presentation on Tuesday, January 25th at 9:00 AM ET PHILADELPHIA, PA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today announced that David Baker, President and Chief Executive Officer will present at the Virtual Investor 2022
Vallon Pharmaceuticals Presents New Data from Adult Stimulant Abuse Pattern Survey at the APSARD 2022 Annual Conference
- Survey results reinforce existing literature that immediate-release (IR) amphetamines, such as Adderall®, are the most commonly abused preparation of prescription stimulants - Company’s abuse-deterrent stimulant formulations have the potential to address misuse and abuse of stimulant medication by non-oral routes, such as snorting - Pivotal abuse study of the Company’s lead investigational program ADAIR completed enrollment and dosing with topline data expected this quarter PHILADELPHIA, PA, J
VLON Price Returns